Why do Trials for Alzheimer's Disease Drugs Keep Failing? A Discontinued Drug Perspective for 2010-2015.
Publication/Presentation Date
6-1-2017
Abstract
INTRODUCTION: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug. Data for these compounds were sought through a PubMed search and a clinicaltrials.gov search. Expert opinion: The obvious question to be posed is: Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate? This review summarizes the drugs that have failed during 2010-2015 and offers possible theories as to why they have failed.
Volume
26
Issue
6
First Page
735
Last Page
739
ISSN
1744-7658
Published In/Presented At
Mehta, D., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. (2017). Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opinion On Investigational Drugs, 26(6), 735-739. doi:10.1080/13543784.2017.1323868
Disciplines
Medical Sciences | Medicine and Health Sciences | Neurology
PubMedID
28460541
Department(s)
Department of Medicine, Department of Medicine Fellows and Residents
Document Type
Article